Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|July 10, 2025
What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomesJuan Pablo Frias
Expert Review of Endocrinology & Metabolism|February 7, 2019
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetesJuan Pablo Frias
Diabetes, Obesity & Metabolism|July 31, 2026
Is Hypercortisolism Treatable? Which Patients Should Be Treated and How-A Practical Guide for CliniciansJuan Pablo Frias
Current Diabetes Reports|August 20, 2017
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal InsulinPatrick F Frias, Juan Pablo Frias
The Review of Diabetic Studies : RDS|May 15, 2023
Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical TrialsHernando Vargas-Uricoechea, Juan Pablo Frias, Hernando David Vargas-Sierra
Obesity (Silver Spring, Md.)|January 25, 2023
Obesity among Latinx people in the United States: A reviewJosé Orlando Alemán, Jaime P Almandoz, Juan Pablo Frias, et al.
Current Medical Research and Opinion|October 27, 2018
Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetesJuan Pablo Frias, Martin Lorenz, Michelle Roberts, et al.
Diabetes Care|June 7, 2022
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled TrialJuan Pablo Frias, JaeDuk Choi, Julio Rosenstock, et al.
Hepatology Communications|April 16, 2021
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASHStephen A Harrison, Mustafa Bashir, Sam E Moussa, et al.
Obesity (Silver Spring, Md.)|December 7, 2018
Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 StudyEdgar D Charles, Brent A Neuschwander-Tetri, Juan Pablo Frias, et al.
Pageof 3